BCM
CGEM icon

Boone Capital Management’s Cullinan Oncology CGEM Stock Holding History

Boone Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
+704,442
New +$10.5M 3% 15

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Boone Capital Management's CGEM Position: Q2 2026 in Review

Boone Capital Management opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 704,442 shares worth $12.8M. The stake represents 3% of the portfolio and ranks #15 among its holdings.

183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Boone Capital Management held 704,442 shares of Cullinan Oncology worth $12.8M as of Q2 2026.
  • Cullinan Oncology was a new Boone Capital Management position in Q2 2026.
  • Cullinan Oncology made up 3% of Boone Capital Management's portfolio in Q2 2026, its #15 holding.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Boone Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.